KCKenneth C. Copeland

Kenneth C. Copeland

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kenneth C. Copeland has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mini-Puberty and Growth

    by Kenneth C. Copeland, Steven Chernausek

    * Abbreviation: IGF-1 — : insulinlike growth factor-1 Within the first few months of life, the human infant experiences a transient activation of the hypothalamo-pituitary-gonadal axis. First described in the 1970s, after the development of assay methodology sufficiently sensitive to detect low levels of hormones in blood,1 this process has been described as a “mini-puberty.” Its purpose remains unclear, but is most commonly thought to be an important developmental event related to subsequent reproductive function.2,3 Mini-puberty occurs in both sexes, with an increase in testosterone in boys and increase in both estradiol and testosterone in girls (testosterone concentrations in girls are ∼30% lower than those in boys at peak). Resultant effects on the reproductive organs include testicular, penile, and prostate growth in boys, uterine and breast enlargement in girls, and sebaceous gland and acne development in both sexes. Effects of this early activation of the hypothalamo-pituitary-gonadal axis are not confined to the reproductive organs, however. Recent evidence suggests that the androgen exposure of mini-puberty also predicts later sex-typed behavior.4,5 In this issue of Pediatrics , Kiviranti et al6 describe yet another effect of this neonatal androgen … Address correspondence to Kenneth C. Copeland, MD, 1200 N. Children’s Ave, Oklahoma University Physicians Building, Ste 4500, Oklahoma City, OK 73104. E-mail: kenneth-copeland{at}ouhsc.edu


  • Self-Reported Dietary Intake of Youth with Recent Onset of Type 2 Diabetes: Results from the TODAY Study

    by Linda Delahanty, Andrea Kriska, Sharon Edelstein, Nancy Amodei, Jennifer Chadwick, Kenneth Copeland, Bryan Galvin, Laure El Ghormli, Morey Haymond, Megan M. Kelsey, et al.


  • Current Treatment Options for Type 2 Diabetes Mellitus in Youth: Today’s Realities and Lessons from the TODAY Study

    by Minu M. George, Kenneth C. Copeland

    The incidence of type 2 diabetes in children and adolescents has increased over the last 2 decades, paralleled by an increase in obesity over the same time period. Although the value of lifestyle modification in obese youth is unquestioned, scant evidence for optimal treatment of type 2 diabetes in this age group exists. Despite recent therapeutic drug trials, metformin and insulin are the only medicines currently approved by the U.S. Food and Drug Administration for the treatment of type 2 diabetes in youth. Because of recently amended pharmaceutical regulations, however, it is likely that more antidiabetic medications soon will be added to the armamentarium of therapeutic options for youth with type 2 diabetes. Additionally, the recently published TODAY study comparing safety and efficacy of three treatment regimens in maintaining glycemic control in youth with type 2 diabetes has shed new light on the problem.


  • Open Access

    Characteristics of Adolescents and Youth with Recent-Onset Type 2 Diabetes: The TODAY Cohort at Baseline

    by Kenneth C. Copeland, Philip Zeitler, Mitchell Geffner, Cindy Guandalini, Janine Higgins, Kathryn Hirst, Francine R. Kaufman, Barbara Linder, Santica Marcovina, Paul McGuigan, et al.

    Context: The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) cohort represents the largest and best-characterized national sample of American youth with recent-onset type 2 diabetes. Objective: The objective of the study was to describe the baseline characteristics of participants in the TODAY randomized clinical trial. Design: Participants were recruited over 4 yr at 15 clinical centers in the United States (n = 704) and enrolled, randomized, treated, and followed up 2–6 yr. Setting: The study was conducted at pediatric diabetes care clinics and practices. Participants: Eligible participants were aged 10–17 yr inclusive, diagnosed with type 2 diabetes for less than 2 yr and had a body mass index at the 85th percentile or greater. Interventions: After baseline data collection, participants were randomized to one of the folllowing groups: 1) metformin alone, 2) metformin plus rosiglitazone, or 3) metformin plus a lifestyle program of weight management. Main Outcome Measures: Baseline data presented include demographics, clinical/medical history, biochemical measurements, and clinical and biochemical abnormalities. Results: At baseline the cohort included the following: 64.9% were female; mean age was 14.0 yr; mean diabetes duration was 7.8 months; mean body mass index Z-score was 2.15; 89.4% had a family history of diabetes; 41.1% were Hispanic, 31.5% were non-Hispanic black; 38.8% were living with both biological parents; 41.5% had a household annual income of less than $25,000; 26.3% had a highest education level of parent/guardian less than a high school degree; 26.3% had a blood pressure at the 90th percentile or greater; 13.6% had a blood pressure at the 95th percentile or greater; 13.0% had microalbuminuria; 79.8% had a low high-density lipoprotein level; and 10.2% had high triglycerides. Conclusions: The TODAY cohort is predominantly from racial/ethnic minority groups, with low socioeconomic status and a family history of diabetes. Clinical and biochemical abnormalities and comorbidities are prevalent within 2 yr of diagnosis. These findings contribute greatly to our understanding of American youth with type 2 diabetes.


  • Open Access

    Normal sex differences in prenatal growth and abnormal prenatal growth retardation associated with 46,XY disorders of sex development are absent in newborns with congenital adrenal hyperplasia due to 21-hydroxylase deficiency

    by Laura J Chalmers, Paul Doherty, Claude J Migeon, Kenneth C Copeland, Brianna C Bright, Amy B Wisniewski

    Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is the most common presentation of a disorder of sex development (DSD) in genetic females. A report of prenatal growth retardation in cases of 46,XY DSD, coupled with observations of below-optimal final height in both males and females with congenital adrenal hyperplasia due to 21-hydroxylase deficiency, prompted us to investigate prenatal growth in the latter group. Additionally, because girls with congenital adrenal hyperplasia are exposed to increased levels of androgens in the absence of a male sex-chromosome complement, the presence or absence of typical sex differences in growth of newborns would support or refute a hormonal explanation for these differences.


  • Open Access

    Vascular health in children and adolescents: effects of obesity and diabetes

    by Kenneth Copeland, Kevin R Short, Piers R Blackett, Andrew W Gardner

    Vascular health in children and adolescents: effects of obesity and diabetes Kevin R Short, Piers R Blackett, Andrew W Gardner, Kenneth C CopelandDepartment of Pediatrics, Section of Diabetes and Endocrinology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA The foundations for cardiovascular disease in adults are laid in childhood and accelerated by the presence of comorbid conditions, such as obesity, diabetes, hypertension, and dyslipidemia. Early detection of vascular dysfunction is an important clinical objective to identify those at risk for subsequent cardiovascular morbidity and events, and to initiate behavioral and medical interventions to reduce risk. Typically, cardiovascular screening is recommended for young adults, especially in people with a family history of cardiovascular conditions. Children and adolescents were once considered to be at low risk, but with the growing health concerns related to sedentary lifestyle, poor diet and obesity, cardiovascular screening may be needed earlier so that interventions to improve cardiovascular health can be initiated. This review describes comorbid conditions that increase cardiovascular risk in youth, namely obesity and diabetes, and describes noninvasive methods to objectively detect vascular disease and quantify vascular function and structure through measurements of endothelial function, arterial compliance, and intima-media thickness. Additionally, current strategies directed toward prevention of vascular disease in these populations, including exercise, dietary interventions and pharmacological therapy are described.Keywords: endothelial function, arterial compliance, intimal medial thickness, inflammation, intervention


    • 5 October 2006
      • Vol. 99  (7) , 439-43

    Ethnic differences in fasting glucose, insulin resistance and lipid profiles in obese adolescents.

    by Evan Moore, Kenneth C Copeland, Don Parker, Christie Burgin, Piers R Blackett

    Children and adolescents with obesity are increasingly referred to the pediatric endocrinology clinic at OU Children's Hospital for evaluation and initiation of preventive measures. During the summer of 2004 we conducted a retrospective review of cases to determine the prevalence of fasting insulin resistance and dyslipidemia; to study associations and differences due to ethnic background; and compare values with similar patients seen at four Indian Health Service clinics. We observed the highest prevalence of dyslipidemia in Caucasian youth. The prevalence of high fasting glucose and mean glucose values were higher in the obese Native American youth than in African Americans or Caucasians. The elevated glucose levels in young Native Americans may be associated with their increased risk for type 2 diabetes compared to other races; but Caucasians are more prone to dyslipidemia. Effective methods are needed to detect, prevent and treat diabetes and cardiovascular risk in children and adolescents.


    • 1 January 2006
      • Vol. 99  (1) , 19-24

    Acanthosis Nigricans, insulin resistance (HOMA) and dyslipidemia among Native American children.

    by Kenneth Copeland, Kim Pankratz, Valari Cathey, Peggy Immohotichey, Janet Maddox, Beverly Felton, Ron McIntosh, Donald Parker, Christie Burgin, Piers Blackett

    It is controversial whether acanthosis nigricans is an independent marker of insulin resistance. In this study, we evaluated whether insulin resistance (as reflected by HOMA) was associated with acanthosis nigricans, Native American heritage, BMI, fasting insulin, and plasma lipids in Native American children and adolescents. Retrospective chart review of Native American children (3.6 to 17.8 yrs) seen in 4 tribal or Indian Health Service clinics after referral for exceptionally high type 2 diabetes risk (family history, extreme obesity, and/or severe acanthosis nigricans). All but 2 had a family history of type 2 diabetes in at least one first or second degree relative, all but 3 had acanthosis nigricans (12 severe and 11 mild/not severe), and all but 2 were obese (BMI Z score of +3 to +8). Those with severe acanthosis nigricans had higher BMI and fasting insulin levels and lower HDL-C (p < 0.05) than those with acanthosis nigricans that was not severe. HDL-C correlated with BMI Z-score (p = 0.046) and approached significance with fasting insulin. HOMA correlated with BMI (p = 0.0005), with 82.4% of males and 33.3% of females having a HOMA greater than the 90th percentile for normal children. A multiple regression model indicated that acanthosis nigricans severity remained a predictor (p = 0.015) of HOMA after association of BMI Z score, Native American blood quantum, and gender were removed. These data indicate that among Native American children at high risk for developing type 2 diabetes, acanthosis nigricans is an independent marker of insulin resistance (as reflected by HOMA).


  • Type 2 Diabetes in Children: Oxymoron or Medical Metamorphosis?

    by Kenneth C Copeland, Laura J Chalmers, Ryan D Brown

    The articles prior to January 2008 are part of the back file collection and are not available with a current paid subscription. To access the article, you may purchase it or purchase the complete back file collection here Kenneth C Copeland, MD; Laura J Chalmers, MD; Ryan D Brown, MD Before the 1990s, a diagnosis of "juvenile" diabetes meant type 1 diabetes, and the rare child or adolescent diagnosed with type 2 diabetes was considered an anomaly. During the past decade, pediatricians have witnessed a profound change in the epidemiology of diabetes, so that the "adult-onset" form of diabetes, previously relegated mostly to that associated with adiposity acquired in middle or older age, now is being diagnosed in children and adolescents at an alarming rate. This observation comes as no surprise, given the almost invariable association between obesity and type 2 diabetes and the new epidemic of obesity in childhood. OBESITY IN CHILDHOOD AND ADOLESCENCE Changing Epidemiology The prevalence of obesity in the United States is increasing in all age groups. Between 1991 and 1998, the number of obese people in the US increased from 12% to 19%,! and the number of states in which 15% or more of the population was obese increased from 4 to 39 of 45 states surveyed.2 According to data from the National Health and Nutrition Examination Surveys (NHANES),3 the number of overweight (defined as a body mass index, BMI, greater than the 95th percentile) children and adolescents increased from approximately 5% in the 1970s to more than 15% by 1999. This trend is even more striking among ethnic minority children, with more than 23% of Mexican American and African American adolescents currently being overweight;4 this trend in ethnicity for obesity mirrors closely the recent trend in the occurrence of type 2 diabetes in these same ethnic groups.5 This increase in obesity prevalence is associated with several recent societal changes in eating habits. Today, high-calorie (especially in the form of high-fructose corn syrup6), high-fat,7 low-fiber foods are plentiful and cheap,8,9 and their ready availability is conducive to recent changes in the home, at work, and at school. During the past 4 decades, obesity has become big business, with extensive food marketing and promotion to children10 fueled by an invasion of cheap and potent sweeteners11 and tasty fats.12 The marketing practice of "value meals" and "super-sizing," combined with the idea that a child will overeat if excess food is provided, creates sinister synergy in the pathogenesis of childhood obesity.12 It thus follows that several well-known complications of obesity, including type 2 diabetes, are emerging as new public health problems for children and adolescents. Known Contributing Factors East foods. Only 38% of meals in the US today are home-cooked; thus the proliferation of fast food restaurants (170,000 in the US alone) should come as no surprise.13 Fast food has become a dietary staple for children both in the US and worldwide.14 Recently, Bowman et al.15 showed that, on a typical day, 30.3% of 6,212 US children reported eating fast food. This resulted in a higher consumption of total energy (187 kcal), 24 more grams of total carbohydrates, 9 more grams of total fat, and 228 more grams of sugar-sweetened beverages when compared with children who did not eat fast food. From 1970 to the mid 1990s, the total energy intake from fast food increased from 2% to 10%,16 prompting a political and social debate about whether the incorporation of fast food into a diet can be considered healthy.17 Although it has been stated that the obesity epidemic may be related to unsafe neighborhoods (rendering it unsafe to go outside to play) and proximity to fast-food restaurants, Burdette et al.18 found no relationships between the distances from home to neighborhood playgrounds or to fast-food restaurants, nor to the amount of neighborhood crime in low-income overweight preschool children. Soft drinks. Sodas, fruit-flavored drinks, and sport drinks are being consumed… 10.3928/0090-4481-20050901-09